Overview

A Phase 1b Study of LAPS-Exendin in Subjects of Type 2 Diabetes Mellitus

Status:
Unknown status
Trial end date:
2014-12-01
Target enrollment:
Participant gender:
Summary
A Phase 1b, Exploratory, Randomized, Partially Single Blinded, Placebo and Open Label Controlled, Parallel Group Study to Assess the Effects of HM11260C and an Active Comparator on Gastric Emptying and Beta-Cell Response in Subjects with Type 2 Diabetes Mellitus
Phase:
Phase 1
Details
Lead Sponsor:
Hanmi Pharmaceutical Company Limited
Treatments:
Exenatide
Liraglutide